|
|
|
|
LEADER |
03661 am a22004933u 4500 |
001 |
117745 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Karver, Mark R.
|e author
|
100 |
1 |
0 |
|a Harvard University-
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Chemistry
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Materials Science and Engineering
|e contributor
|
100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
100 |
1 |
0 |
|a Moynihan, Kelly Dare
|e contributor
|
100 |
1 |
0 |
|a Holden, Rebecca Lynn
|e contributor
|
100 |
1 |
0 |
|a Mehta, Naveen
|e contributor
|
100 |
1 |
0 |
|a Wang, Chensu
|e contributor
|
100 |
1 |
0 |
|a Liang, Simon
|e contributor
|
100 |
1 |
0 |
|a Abraham, Wuhbet
|e contributor
|
100 |
1 |
0 |
|a Melo, Mariane Bandeira
|e contributor
|
100 |
1 |
0 |
|a Zhang, Angela Q.
|e contributor
|
100 |
1 |
0 |
|a Li, Na
|e contributor
|
100 |
1 |
0 |
|a Pentelute, Bradley L.
|e contributor
|
100 |
1 |
0 |
|a Irvine, Darrell J
|e contributor
|
700 |
1 |
0 |
|a Dinter, Jens
|e author
|
700 |
1 |
0 |
|a Gall, Sylvie Le
|e author
|
700 |
1 |
0 |
|a Moynihan, Kelly Dare
|e author
|
700 |
1 |
0 |
|a Holden, Rebecca Lynn
|e author
|
700 |
1 |
0 |
|a Mehta, Naveen
|e author
|
700 |
1 |
0 |
|a Wang, Chensu
|e author
|
700 |
1 |
0 |
|a Liang, Simon
|e author
|
700 |
1 |
0 |
|a Abraham, Wuhbet
|e author
|
700 |
1 |
0 |
|a Melo, Mariane Bandeira
|e author
|
700 |
1 |
0 |
|a Zhang, Angela Q.
|e author
|
700 |
1 |
0 |
|a Li, Na
|e author
|
700 |
1 |
0 |
|a Pentelute, Bradley L.
|e author
|
700 |
1 |
0 |
|a Irvine, Darrell J
|e author
|
245 |
0 |
0 |
|a Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability
|
260 |
|
|
|b American Association for Cancer Research,
|c 2018-09-13T18:20:51Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/117745
|
520 |
|
|
|a Antitumor T-cell responses have the potential to be curative in cancer patients, but the induction of potent T-cell immunity through vaccination remains a largely unmet goal of immunotherapy. We previously reported that the immunogenicity of peptide vaccines could be increased by maximizing delivery to lymph nodes (LNs), where T-cell responses are generated. This was achieved by conjugating the peptide to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-PEG (DSPE-PEG) to promote albumin binding, which resulted in enhanced lymphatic drainage and improved T-cell responses. Here, we expanded upon these findings and mechanistically dissected the properties that contribute to the potency of this amphiphile-vaccine (amph-vaccine). We found that multiple linkage chemistries could be used to link peptides with DSPE-PEG, and further, that multiple albumin-binding moieties conjugated to peptide antigens enhanced LN accumulation and subsequent T-cell priming. In addition to enhancing lymphatic trafficking, DSPE-PEG conjugation increased the stability of peptides in serum. DSPE-PEG peptides trafficked beyond immediate draining LNs to reach distal nodes, with antigen presented for at least a week in vivo, whereas soluble peptide presentation quickly decayed. Responses to amph-vaccines were not altered in mice deficient in the albumin-binding neonatal Fc receptor (FcRn), but required Batf3-dependent dendritic cells (DCs). Amph-peptides were processed by human DCs equivalently to unmodified peptides. These data define design criteria for enhancing the immunogenicity of molecular vaccines to guide the design of next-generation peptide vaccines.
|
520 |
|
|
|a National Cancer Institute (U.S.) (Grant P30-CA14051)
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Cancer Immunology Research
|